ELOVL6 regulates resistance to BTZ in MM cells. (A-B) MM cells were treated or not with BTZ for the indicated time periods followed by immunoblotting with the indicated antibodies. (C) MM cells were transduced with control (CL) or ELOVL6 shRNAs (E1 or E2) followed by immunoblotting with the indicated antibodies 48 hours postinfection. (D) Cells described in panel C were treated for 16 hours with the indicated amounts of BTZ and probed in immunoblotting with the indicated antibodies (before the onset of cell death). (E) Cells described in panel C were treated with the indicated amounts of BTZ for 24 hours and probed in trypan blue cell viability assay. (F) MM cells were transduced with empty lentiviral vector (V) or lentiviral vector expressing ELOVL6 cDNA (ELOVL6) followed by immunoblotting with indicated antibodies 48 hours postinfection. (G) Cells described in panel F were treated for 16 hours with the indicated amounts of BTZ and probed in immunoblotting with the indicated antibodies (before the onset of cell death). (H) Cells described in panel F were treated for 24 hours with indicated amounts of BTZ and probed in trypan blue cell viability assay. Shown immunoblots are representative images of at least 2 independent experiments with no tangible experimental variability. The viability data are presented as the mean values of triplicates ± standard errors of the mean. P values were determined by Student t test. *P < .05, **P < .01.